Investment Thesis
Arrowhead Pharmaceuticals shows compelling fundamental momentum with extraordinary 23,258% revenue growth indicating successful product commercialization, coupled with a fortress balance sheet (minimal debt, 6.23x liquidity) and positive free cash flow of $93.2M, suggesting the business model is economically viable. While current profitability metrics are severely negative (~-30% margins), this reflects typical early-stage commercialization investment patterns in pharma, and the company has sufficient financial resources and operational cash generation to reach profitability if revenue sustains.
Strengths
- Extraordinary revenue growth (23,258% YoY) indicates successful major product launch or commercial milestone
- Positive free cash flow of $93.2M (27.6% FCF margin) despite net losses demonstrates underlying business viability
- Fortress balance sheet with minimal debt ($1.0M), strong equity ($614.0M), and exceptional liquidity (6.23x current ratio) provides runway and financial flexibility
Risks
- Severe profitability deficit with -29.7% operating margin and -30.2% net margin creates ongoing cash burn at operations level
- Significant disconnect between positive free cash flow and negative net income ($97.9M operating cash flow vs -$101.9M net income) suggests substantial non-cash charges or potential accounting complexity requiring clarification
- Negative returns on capital (ROE -16.6%, ROA -4.5%) indicate poor capital efficiency currently, with execution risk on pipeline programs and profitability timeline
Key Metrics to Watch
- Operating margin trajectory and path to profitability over next 2-4 quarters
- Revenue growth sustainability and product adoption rates across commercialized pipeline
- Operating cash flow consistency and reconciliation with net income convergence
Financial Metrics
Revenue
337.8M
Net Income
-101.9M
EPS (Diluted)
$-0.73
Free Cash Flow
93.2M
Total Assets
2.3B
Cash
188.5M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-29.7%
Net Margin
-30.2%
ROE
-16.6%
ROA
-4.5%
FCF Margin
27.6%
Balance Sheet & Liquidity
Current Ratio
6.23x
Quick Ratio
6.23x
Debt/Equity
0.00x
Debt/Assets
0.0%
Interest Coverage
-7.97x
Long-term Debt
1.0M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-09T09:35:14.654914 |
Data as of: 2026-03-31 |
Powered by Claude AI